Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31472061 | 0.88 | — | — | |
| SCHEMBL15518859 | 0.79 | BRD4 (0.36) | HTTSMN1; SMN2CCR4MAPTKDM4E | |
| SCHEMBL13676392 | 0.79 | PIP4K2A (0.38) | CCR4APPTRPA1MAOBCDK2 | |
| SCHEMBL29769114 | 0.79 | PIP4K2A (0.38) | CCR4APPTRPA1MAOBCDK2 | |
| SCHEMBL23115842 | 0.78 | MAOB (0.36) | HTTSMN1; SMN2GAAAPPMAPT | |
| SCHEMBL20015374 | 0.78 | CCR4 (0.39) | CCR4MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL31424338 | 0.78 | PI4KA (0.37) | CCR4APPMAPTALDH1A1TRPA1 | |
| SCHEMBL31500712 | 0.78 | PI4KA (0.37) | CCR4MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL16738868 | 0.78 | IDO1 (0.32) | CCR4GAAMAPTKDM4EMEN1 | |
| SCHEMBL31500705 | 0.78 | ALDH1A1 (0.32) | CCR4MAPTKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2025124357-A9 | HETEROCYCLIC GLP-1 RECEPTOR AGONIST AND USE THEREOF | 广东众生睿创生物科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| CN-122010981-A | GLP-1 receptor agonism/GLP-1 secretagogue double-target compound | 仁奎医药科技(北京)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | BIOMEA FUSION, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-16 | — | — | US | disclosed |
| CN-121850947-A | Preparation method of GLP-1 agonist intermediate and compound | 成都博腾药业有限公司 | 2026-04-14 | — | — | CN | disclosed |
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-02-26 | — | — | US | disclosed |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | CHONGQING PHARMACEUTICAL RES INSTITUTE CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| CN-110740991-A | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2020-01-31 | — | — | CN | disclosed |
| EP-3517538-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | Chugai Seiyaku Kabushiki Kaisha (JP) | 2019-07-31 | — | — | EP | disclosed |
| EP-3517538-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | Chugai Seiyaku Kabushiki Kaisha (JP) | 2019-07-31 | — | — | EP | disclosed |
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20180354960-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-3381896-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-03 | — | — | EP | disclosed |
| WO-2018056453-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | 中外製薬株式会社 | 2018-03-29 | — | — | WO | disclosed |
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | HTT 2783/4885SMN1; SMN2 3453/4885CCR4 4075/4885 |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | MET, ERBB2, ALK | HTT 3764/4885SMN1; SMN2 765/4885CCR4 2400/4885 |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | GLP1R, GIPR, GPR119 | HTT 2184/4885SMN1; SMN2 3598/4885CCR4 1573/4885 |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GPR119 | HTT 1647/4885SMN1; SMN2 3547/4885CCR4 303/4885 |
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | HTT 2254/4885SMN1; SMN2 2362/4885CCR4 665/4885 |
| US-20180354960-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | KDM1B, HDAC1, DOT1L | HTT 3125/4885SMN1; SMN2 2791/4885CCR4 4056/4885 |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | HTT 3268/4885SMN1; SMN2 2889/4885CCR4 1136/4885 |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | HTT 1595/4885SMN1; SMN2 2057/4885CCR4 3950/4885 |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GIPR, GPR119 | HTT 3315/4885SMN1; SMN2 2230/4885CCR4 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.